Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1019853-74-7

C14H11F2N5O is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1019853-74-7 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1019853-74-7 Structure

  • Basic information

    1. Product Name: C14H11F2N5O
    2. Synonyms: C14H11F2N5O
    3. CAS NO:1019853-74-7
    4. Molecular Formula:
    5. Molecular Weight: 303.271
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1019853-74-7.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: C14H11F2N5O(CAS DataBase Reference)
    10. NIST Chemistry Reference: C14H11F2N5O(1019853-74-7)
    11. EPA Substance Registry System: C14H11F2N5O(1019853-74-7)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1019853-74-7(Hazardous Substances Data)

1019853-74-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1019853-74-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,1,9,8,5 and 3 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1019853-74:
(9*1)+(8*0)+(7*1)+(6*9)+(5*8)+(4*5)+(3*3)+(2*7)+(1*4)=157
157 % 10 = 7
So 1019853-74-7 is a valid CAS Registry Number.

1019853-74-7Upstream product

1019853-74-7Downstream Products

1019853-74-7Relevant articles and documents

Synthesis and activity of novel 5-substituted pyrrolo[2,3-d]pyrimidine analogues as pp60c-Src tyrosine kinase inhibitors

Oelgen, Suereyya,Isgoer, Yasemin G.,Coban, Tuelay

experimental part, p. 113 - 120 (2009/04/04)

Therapy with receptor tyrosine kinase inhibitors provides an improved treatment option in a number of diseases such as cancer, myocardial infection, osteoporosis, stroke, and neurodegeneration. We have designed, synthesized, and evaluated a series of nove

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1019853-74-7